Rogier Rooswinkel
Directeur/Membre du Conseil chez Amphista Therapeutics Ltd.
Profil
Rogier is a General Partner at the Naarden office and joined Forbion in 2013.
Rogier is responsible for evaluation and structuring of new investment opportunities across all disease areas with an emphasis on oncology.
He was among others closely involved in the investments in Rigontec, Replimune, Enterprise, KaNDy and setting up of the university spin-out Catalym.
He currently serves as a board member for Amphista, Catalym, and Tessellate and as a board observer for Enterprise, Prilenia, and Escalier.
Previously, Rogier was a board director of Achilles ($ACHL) and an observer at Replimune ($REPL)
Rogier joined Forbion in 2013.
Prior to joining Forbion, Rogier worked as a post-doc at the Netherlands Cancer Institute (NKI), division of immunology.
During his studies, Rogier was active as an independent website designer and founded an IT-company.
In 2013 he received his PhD degree Cum Laude from the University of Amsterdam for the work he performed at the NKI.
Before that, he received a Master’s degree in Oncology at the VU university of Amsterdam
Postes actifs de Rogier Rooswinkel
| Sociétés | Poste | Début |
|---|---|---|
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 01/01/2018 |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | - |
Amphista Therapeutics Ltd.
 Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Directeur/Membre du Conseil | - |
Formation de Rogier Rooswinkel
| Vrije Universiteit Amsterdam | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
 | Health Technology |
| Entreprise privées | 2 |
|---|---|
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
Amphista Therapeutics Ltd.
Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Health Technology |
